Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia - Cost effectiveness and risk sharing

John H Wlodarczyk; Leslie G Cleland; Anne Keogh; Keith D McNeil; Kate Perl; Rogert G Weintraub; Trevor John Williams

Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia - Cost effectiveness and risk sharing

John H Wlodarczyk, Leslie G Cleland, Anne Keogh, Keith D McNeil, Kate Perl, Rogert G Weintraub, Trevor John Williams

Medicine Alfred Hospital

Research output: Contribution to journal › Article › Other

Original language	English
Pages (from-to)	903 - 915
Number of pages	13
Journal	PharmacoEconomics
Volume	24
Issue number	9
Publication status	Published - 2006

Cite this

@article{2b5cb9b52e414f66bd6470723d0e37e0,

title = "Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia - Cost effectiveness and risk sharing",

author = "Wlodarczyk, {John H} and Cleland, {Leslie G} and Anne Keogh and McNeil, {Keith D} and Kate Perl and Weintraub, {Rogert G} and Williams, {Trevor John}",

year = "2006",

language = "English",

volume = "24",

pages = "903 -- 915",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Springer",

number = "9",

}

TY - JOUR

T1 - Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia - Cost effectiveness and risk sharing

AU - Wlodarczyk, John H

AU - Cleland, Leslie G

AU - Keogh, Anne

AU - McNeil, Keith D

AU - Perl, Kate

AU - Weintraub, Rogert G

AU - Williams, Trevor John

PY - 2006

Y1 - 2006

UR - http://<Go to ISI>://000240669900007

M3 - Article

SN - 1170-7690

VL - 24

SP - 903

EP - 915

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 9

ER -

Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia - Cost effectiveness and risk sharing

Other files and links

Cite this